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ABSTRACT  
   
African Swine Fever (ASF), endemic in many African countries, is 
now spreading to other continents. Though ASF is capable of incurring 
serious economic losses in affected countries, no vaccine exists to provide 
immunity to animals. Disease control relies largely on rapid diagnosis and 
the implementation of movement restrictions and strict eradication 
programs. Developing a scalable, accurate and low cost diagnostic for 
ASF will be of great help for the current situation. CIM's 10K random 
peptide microarray is a new high-throughput platform that allows 
systematic investigations of immune responses associated with disease 
and shows promise as a diagnostic tool. In this study, this new technology 
was applied to characterize the immune responses of ASF virus (ASFV) 
infections and immunizations. Six sets of sera from ASFV antigen 
immunized pigs, 6 sera from infected pigs and 20 sera samples from 
unexposed pigs were tested and analyzed statistically. Results show that 
both ASFV antigen immunized pigs and ASFV viral infected pigs can be 
distinguished from unexposed pigs. Since it appears that immune 
responses to other viral infections are also distinguishable on this platform, 
it holds the potential of being useful in developing a new ASF diagnostic. 
The ability of this platform to identify specific ASFV antibody epitopes was 
also explored. A subtle motif was found to be shared among a set of 
peptides displaying the highest reactivity for an antigen specific antibody. 
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However, this motif does not seem to match with any antibody epitopes 
predicted by a linear antibody epitope prediction.  
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Chapter 1 
INTRODUCTION 
Overview 
African swine fever (ASF) is a hemorrhagic disease that is widespread 
in Africa and continues to spread to other continents. It is considered as 
List A disease by the Office International des Epizootics (OIE). Due to its 
high mortality rates and its wide host range, it can cause major economic 
losses in those affected countries (Costard, Wieland et al. 2009). ASF is 
caused by ASF virus (ASFV), a large double-stranded DNA virus that was 
classified as the only member of the Asfarviridae family. ASFV can infect 
both wild and domestic porcine species. There is no effective vaccine 
available for ASFV. The control and eradication strategies mainly rely on 
rapid and effective laboratory diagnosis, the enforcement of strict sanitary 
regulations, and slaughter. Although recently developed techniques such 
as real-time PCR tests have proved to be useful in identifying ASFV 
infection, detection of ASFV-specific antibodies remains the major method 
of diagnosis. A antibody profiling assay based on our center’s 10K random 
peptide microarray has been successfully used to investigate the disease-
associated changes for many diseases (Boltz, Gonzalez-Moa et al. 2009; 
Legutki, Magee et al. 2010; Halperin, Stafford et al. 2011). In this study, 
we took advantage of this new technology to analyze host immune 
responses to ASFV relative to viral infection and antigen immunization and 
explored its potential for ASF diagnosis.     
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Statement of Problem 
Similar to other viral diseases, ASF diagnosis is typically based on the 
detection of infectious virus, viral antigens, viral DNA or viral specific 
antibodies. Serum antibodies are not only used as indexes of ASFV 
infections, but also can be used to study sub-acute and chronic forms of 
ASF (Perez-Filgueira, Gonzalez-Camacho et al. 2006). Therefore, 
although many laboratory tests for ASF are available, the serological 
studies are the most important. The Enzyme-Linked Immunosorbent 
Assay (ELISA) test is currently the most useful serological method for 
large scale diagnosis (Gonzague, Roger et al. 2001). Viral antigens used 
in the ELISA tests are either derive from live virus or recombinantly 
produced. Viral antigens derive from virus involve manipulation of the 
infectious agent thus have safety concerns and the production of the 
recombinant viral proteins is not cost efficient (Perez-Filgueira, Gonzalez-
Camacho et al. 2006). Thus, a cheap and scalable serological diagnosis is 
desired.  
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Chapter 2 
Background and Significance 
ASFV 
ASF is a highly contagious and fatal viral disease of pigs caused by 
ASFV, a complex virus that belong to the Asfarviridae family.  ASFV has a 
double stranded linear DNA genome that varies from 170 Kb to 190 Kb 
and encodes between 160 to175 genes, depending on the isolate 
(Costard, Wieland et al. 2009). ASF was first described in Kenya in 1921. 
Since then, it has been acknowledged as endemic disease in many 
African countries. The first outbreak of ASF outside Africa occurred in 
Lisbon (Portugal) in 1957. The most recent outbreak of ASF outside Africa 
started at the beginning of 2007 in Georgia, and has since spread to the 
countries of Armenia, Azerbaijan, Iran and Russia (Rowlands 2008). ASF 
appears mostly as an acute disease in Africa, but mainly subacute or 
chronic forms are found outside of Africa. Clinically, ASF can present a 
range of clinical signs. Some of them are similar to other diseases of pigs. 
The immune mechanisms that related to protection against ASF are not 
thoroughly understood. Although many efforts have been made to develop 
an effective vaccine, there has been no success to date. Effective 
treatments or cures for ASF are also not available at this point. 
Although the United States was listed as one of the top world pork 
import and export countries, efficient surveillance and strict control and 
prevention policies can help us from ASF outbreaks. However, most of 
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African countries, including many countries of South America are less 
developed countries can be easily exposed to the consequences of an 
introduction of ASFV due to their poor surveillance systems and ineffective 
control. Also, extreme climatic events like earthquake and other disasters 
can make these less developed countries even more vulnerable to the 
spread of ASFV. More importantly, many of families from those countries 
are low-income rural families. The infected pigs could be the only livestock 
they owned. Slaughtering their only livestock could be a huge loss to them. 
An accurate detection method would largely improve the chances of the 
disease control and prevent the tragedy from occurring to those poor 
families. Such a detection method must also be cost efficient in order to 
make large scale assessments. Apart from economic consideration, an 
ideal detection of ASFV should also be rapid and accurate, which would 
allow a timely diagnosis and ensure the management of the risk of 
introduction and spread of the disease. However, there are many 
difficulties involved in finding such detection methods. Firstly, ASFV have 
many isolations and it present a lot variations in pathogenesis level which 
make an accurate diagnosis to be very difficult. Also, the similarities of the 
clinical symptoms between ASF and other hemorrhagic diseases, such as 
classical swine fever (CSF), erysipelas, and septicemic salmonellosis. It 
also make the diagnosis more sophisticated (Gallardo, Blanco et al. 2006).  
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ASFV diagnosis 
Currently there are many different laboratory tests have been used for 
the identification of ASFV. Like other viral infections, these diagnoses of 
ASF are based on the demonstration of the infectious virus, viral antigens, 
viral DNA or specific antibodies(Barbara E. Straw 2006). The major tests 
are listed as follow:  
(1) Hemadsorption test. ASFV can be isolated by inoculating blood or 
tissue samples from suspect pig in to leukocyte or bone marrow cultures. 
Most isolates of ASFV can induce hemadsorption of pig erythrocytes to 
the surface of the infected cells. This test is very sensitive and used to 
confirm new outbreaks. However, the non-hemadsorbing isolates can be 
missed by this test(Bustos, Nogal et al. 2002). 
(2) Direct immunofluorescence. It is based on detecting viral antigen in 
impression smears or frozen tissues sections which react with conjugated 
ASFV antibodies. It is a fast test for acute form of ASF, but has low 
diagnostic sensitivity for chronic forms of ASF. The decreased sensitivity 
may relate to the formation of antigen-antibody complexes in tissue could 
block the interaction between the ASFV antigen and in vitro-added 
antibody conjugate(Hess 1981).  
(3) Polymerase Chain Reaction (PCR) assay. PCR assay can be used 
to detect a highly conserved region of the viral genome. It has been used 
to identify all the ASFV isolates (Aguero, Fernandez et al. 2003). PCR 
assay is very useful for detecting acute viral isolates which can kill pigs 
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before the antibody responses is mounted. It is also very helpful in 
putrefied samples that cannot be used for other diagnostic test. Real time 
PCR tests that was recently developed have also been proved to be a 
useful tool for identifying ASFV in infected animals (Zsak, Borca et al. 
2005; Ronish, Hakhverdyan et al. 2011). However, these tests require 
sophisticated equipment and expensive ingredients that not readily 
available in endemic areas. 
(4) Serologic tests are based on the detection of ASF antibodies that 
can persist for long periods after infection. It is widely used in endemic 
regions(Gallardo, Blanco et al. 2006). Although many serologic tests have 
been developed, ELISA is the most widely used tool for large scale 
diagnosis. It has also been standardized for routine used. However, the 
scopes of information provided by the ELISA assay readouts are limited 
and the antigens used these assays are not cheap to produce. Given the 
shortage of ELISA tests, a high throughput microarray seems to be a good 
solution.  
CIM 10K random peptide microarray 
The CIM 10K random peptide microarray consists of approximately 
10,000 random peptides. These 20-mer random sequence peptides were 
predicted using custom software that generates random natural amino 
acids sequences. Nineteen amino acids (except cysteine) were available 
for selection in each of the amino-terminal seventeen positions, and then 
Glycine-Serine-Cysteine were uniformly added to the carboxy-terminus as 
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linkers to keep the other 17 functional residues raised from the glass 
surface(Legutki, Magee et al. 2010). This high throughput screening 
platform has been successfully used in many different applications: 
identifying surface-immobilized peptides which specifically bind bacterial 
lipopolysaccharides (Boltz, Gonzalez-Moa et al. 2009; Morales Betanzos, 
Gonzalez-Moa et al. 2009), guiding production of synthetic 
antibodies(Williams, Diehnelt et al. 2009), characterizing humoral 
response to influenza infections and vaccination, and evaluate Alzheimer’s 
disease(Legutki, Magee et al. 2010; Lucas Restrepo and Johnston 2011).  
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Chapter 3 
RESEARCH HYPOTHESIS 
Although the immune mechanisms that protect against ASF are not 
well understood, we do know that ASFV can elicit high levels of specific 
antibodies during the infection. ASFV IgM can be detected four days after 
infection and ASFV IgG can be detected in the blood six to eight days 
after infection(Sánchez-Vizcaíno 1999). Several widely used diagnostic 
methods that detect antibody responses such as ELISA and 
immunoblotting assay are all based on such knowledge. The CIM 10K 
random peptide microarray consists of 10K random 20 mer peptides that 
are covalently attached at their C-terminus to the glass surface. It has 
been proved to be a very successful platform for detecting many antibody 
reactivates (Boltz, Gonzalez-Moa et al. 2009; Morales Betanzos, 
Gonzalez-Moa et al. 2009; Legutki, Magee et al. 2010). We believe such a 
platform can be used to compare and contrast the antibody reactivates of 
ASFV antigen immunized pigs and ASFV infected pigs. Our recent ELISA 
data that demonstrated that our immunized and non-immunized sera 
carried differences in antibody levels to specific antigens, suggest that 
these sera are appropriate for deeper analysis using our 10K random 
peptide microarray. We hypothesize that our microarray based system can 
distinguish between viral infected pigs from uninfected pigs. Furthermore, 
we hypothesize that this immune assay platform can be used to 
distinguish the antibody responses of infected vs. subunit vaccinated pigs. 
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We also want to test if our system can differentiate ASFV infected pigs 
from pigs infected by other viruses, which has the potential to be very 
practical in the diagnosis for ASF in field settings. Moreover, we want to 
test the sensitivity and the specificity of our random peptide microarray by 
comparing the immune profiles of pigs that were immunized with a set of 
42 different ASFV antigens. The 10K random peptide microarray platform 
may be able to identify random peptides for use in development of a 
simple ASFV diagnostic.  
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Chapter 4 
MATERIALS AND METHODOLOGY 
Research Design 
Overview 
All 48 sera samples were used to probe the CIM 10K random peptide 
microarrays. The scanned images of the slides were then aligned by using 
GenePix Pro 6.0. The median intensities of the peptide signals 
(expression level) were measured and averaged across the replicates. 
Then the signal intensities of all the peptides were then loaded into 
Genespring GX 7.3. To explore the diagnostic potential of our random 
peptide microarray, seven different comparisons of different groups of 
sera were evaluated using one-way analysis of variance (ANOVA) and 
principle component analysis (PCA). To determine the antibody binding 
pattern of different group of sera, the most preventative peptides that were 
selected by ANOVA were used to create the heat map and reveal the PCA 
plot. 
To identify the peptides that can bind to ant-VP30 antibody, the anti-
VP30 antibody depletion test was carried out. VP30 protein was 
synthesized in vitro by using VP30 linear expression elements (LEE) as 
the template, then incubated with ASFV sera to deplete anti-VP30 
antibody. After depletion test, the anti-VP30 antibody was separated from 
VP30 protein by glycin-HCl elution. Both depleted sera and purified anti-
VP30 antibody were collected to probe the 10K random peptide 
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microarray. The peptides that bind to anti-VP30 antibody were then 
compared with the VP30 protein sequence by a motif finding program 
GLAM2SCAN, in order to identify the sequence similarities. Also, these 
peptides were compared with the antibody binding epitopes that predicted 
by Bepipred Linear Epitope Prediction. 
Serum Sources 
Immunized British sera. Four groups of the immunized British sera 
samples were from the ASF vaccine discovery project. The objective of 
this project is to develop a safe and effective component vaccine for ASF 
by vaccinating the pigs with different groups of viral proteins. Such a 
strategy allows us to screen for potentially protective antigens that are not 
normally exposed to or recognized by the immune system. The 
immunizations were conducted with a gene-prime and vaccinia-boost 
regimen. Twenty pigs were split into four groups, five pigs each group. 
Pigs in group 1 were genetically immunized with two known ASFV 
immunogens, VP30 and VP72, along with a pool of 20 randomly selected 
antigens. Groups 2, 3, and 4 were immunized with VP30 and VP72, along 
with 20 randomly selected antigens (different from group 1) for group 2, 10 
membrane protein antigens for group 3, and no additional antigens for 
group 4. All the pigs from four groups were bled before and 10 weeks after 
immunization. 
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Sera from infected French pigs. Sera samples of four ASFV infected 
pigs and two ASFV uninfected pigs were collected from our French 
collaborators. All these pigs were specific pathogen free (SPF).  
Sera from infected British pigs. There are only two sera samples in 
this group: TQ13 and MI92. Both are from OURT88/3 infected pigs 
(OURT88/3 is an ASFV isolate). Unlike the French pigs, these pigs were 
not under pathogen control programs. 
Beads TMB ELISA 
In order to test our protein made by in vitro transcription/translation 
(IVTT) expression, TMB ELISA were performed as follow procedure: (1). 
Add ~0.1ug of protein on beads to wells of a MaxiSorp 96-well plate. 
Remove buffer. Add 100μl of ELISA coating buffer (0.03M NaHCO3, 
0.02M Na2CO3).  Seal plate, incubate 4ºC overnight. (2). Wash the plate 
on magnetic stand 3X with 1X PBS + 0.05% Tween-20 or 1X TBS + 
0.05% Tween-20. (3). Add 200μl of 3% BSA in 1X PBS to all wells, seal 
plate, and incubate at 37ºC for one hour. Meanwhile, prepare serum 
dilutions in 3% BSA in 1X PBS. (4). Wash MaxiSorp plate from step 3 3X 
on magnetic stand. Then, add 100μl of diluted sera from the deep well 
plate in step 4 to the MaxiSorp plate to appropriate wells. Each serum 
dilution should be done in duplicate. Seal the plates and incubate at 37 
degrees for 1 hour.  (5) Wash MaxiSorp plate 3X on magnetic stand. Add 
100μl of 1:3000 dilution of Goat anti-swine IgG (H+L) HRP secondary 
antibody in 3%BSA in 1X PBS to appropriate wells. Seal plate and 
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incubate at 37ºC for one hour. (6) Wash MaxiSorp plate 3X on magnetic 
stand.  Add 100μl of TMB (warmed at room temp ~5 min) to all. Allow 
reaction to proceed until color development is sufficient. (7)100μl of 0.5M 
HCl to each well to stop color development. (8) Read at 450nm in 
SpectraMax M5 within 30 min. of stopping reaction.    
Construction of LEE structure 
Due to the failure of express VP30 protein recombinantly, we switch to 
another protein expression strategy: In Vitro Transcription/Translation 
(IVTT) system. We also take advantage of the Linear Expression 
Elements (LEE) technology in our lab to improve the yield of our interested 
proteins. By LEE technology, we were able to noncovalently link the PCR-
amplified open-reading frame (ORF) to a eukaryotic promoter and 
terminator, which can further used as the template in IVTT reaction(Sykes 
and Johnston 1999). To construct the LEE for VP 30, we first generated 
three cassettes: VP30 open reading frame (ORF), promoter and 
terminator. The 50μl PCR reaction system include: 5.0 μ l 1ng/μl template, 
2.5μl 10μM forward oligo, 2.5μl 10μM reverse oligo, 5.0μl 10X Pfu Turbo 
Buffer, 0.4μl 100mM dNTPs, 1.0μl Pfu Turbo and 33.6μl water. The 
forward and reverse primers we used to amplify VP30 ORF were 
ASFV127_F (ggtataggcggaagcgccatggattttattttaaatatatccatgaaaatggag) 
and ASFV127_R: gtcttcttcgctaatcagtttctgttcaaacattaaatgtaggtgagataaa 
agcttatttt. The primers we used to amplify the promoter were T7_Trx_F 
(gcgaaattaatacgactcactatagg) and T7_Trx_R (cctcgacgctaacctggccggta 
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taggcggaagcgcc). The primers we used to amplify the terminator were T7 
Term His ASFV F (gaacagaaactgattagcgaagaagaccatcatcatcatcattaataaaa 
gggcg) and T7 Term R ASFV (ctgaaaggAggaactatatccggat). The PCR 
conditions were: denature 1 minute at 95ºC, then 95ºC 30 seconds/52ºC 
30 seconds/72ºC 2.0 minutes for 40 cycles. After confirm the length of the 
PCR products by running on 0.8%-1.0% agarose (Lonza) gel, we purify 
remaining product by Qiagen gel extraction kit. Then we did overlapping 
(recursive) PCR to get the full length LEE cassette for VP30. The 50μl 
reaction system was: 10.0μl 160fmol ORF (+ water); 1.0μl 160fmol T7 Trx 
Promoter ASFV (42.35ng); 1.0μl 160fmol T7 Term His ASFV (31.82ng); 
5.0μl 10X Pfu Turbo Buffer; 0.4μl 100mM dNTPs; 1.0μl Pfu Turbo and 
31.6μl water. The PCR conditions were: denature 1 minute at 95ºC, then 
95ºC 30 seconds/52ºC 25 minutes/72ºC 2.5 minutes for 40 cycles. After 
overlapping the three segments, we amplified the whole cassette by 
another round of PCR. The amplification PCR reaction systems were: 
10.0μl   recursive PCR, 4.0μl 10μM F primer: T7 Trx ASFV F new, 4.0μl 
10μM R primer: T7 Term His ASFV R, 8.0 μl 5X iProof Buffer, 0.5μl iProof, 
0.4μl   100mM dNTPs, 23.1μl water. The PCR conditions were: denature 
30 seconds at 98ºC, then 98ºC 10 seconds/58ºC 30 seconds/72ºC 1.5 
minutes for 25 cycles. If the PCR product were confirmed by running a test 
gel, we purify the remaining PCR product by Qiagen PCR purification kit.  
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Protein Expression in E.coli 
The E.coli strain we used was One Shot® BL21 Star™ (DE3) 
Chemically Competent E. coli from Invitrogen. The basic transformation 
procedure is: (1) Thaw one vial of competent cells on ice per 
transformation. (2) Add 5~10 ng of DNA, in a volume of 1~5 μL to the cells 
and mix gently. (3) Incubate the on ice for 30 minutes. (4) Heat shock the 
cells by incubating for exactly 30 seconds in the 42°C water bath. (5) 
Remove it from the 42°C bath and quickly place on ice. (6) Add 250 μL of 
pre-warmed Super Optimal Broth (SOC) medium. (7) Shake the cells at 
37°C for 1 hour at 225 rpm. (8) Plate two different volumes of the 
transformation reaction onto LB plates containing the appropriate antibiotic. 
(9) Invert the plates and incubate at 37°C overnight. 
Once we got the colonies from the plates, we start to induce the protein by 
the protocols as follow: (1) Overnight Culture: Pick up one clear colony 
from a  fresh plate and inoculate it into 10 ml LB media with 50μg/ml 
Carbenicillin. Grow in the Innova 44 Incubator Shaker with 37°C at 250 
rpm. (2) Large culture: Use 1 to 100 dilution of the overnight culture to 
inoculate larger culture of LB media with 50μg/ml Carbenicillin. (3) Allow to 
grow it at 37°C at 250 rpm. Measure the OD600 every 30 minutes by 
Eppendorf Bio photometer. Stop growing until the OD600 reach 0.6. (4) 
Induction: Use the optimized concentration of Isopropyl β-D-1-
thiogalactopyranoside (IPTG) to induce the protein for 2 to 4 hours with 
37°C at 250 rpm shaking. In our case, the optimized concentration of 
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IPTG was 1 mM final concentration (5) Collect the cells. Spin the cells at 
6000Xg for 10 minutes by using centrifuge tube (Nelgene 3141-0250 Wide 
mouth, PPCO). 
After inducement, we prepared E.coli lysis by follow procedure: (1) 
Prepare the suspension buffer: 1XPBS, 1.0% Triton X-100, 1 mM PMSF 
and a protease inhibitor tablet. Then suspend the cell pellet in suspension 
buffer (5 ml for 200 ml LB culture). (2) Dissolve about 10 mg of Lysozyme 
in 500ul of PBS and add to the lysis. (3) Incubate at room temp for 15 min 
with occasional shaking, and then freeze the lysate at -80 ºC for at least 
10 min. (4) Thaw the lysate completely at room temp. (5) Repeat 
Freeze/Thaw two more times and spin the lysate at 27000Xg for 10 min. 
(6) Collect the supernatant and the pellet separately.  
The protein was purifed by using Ni Sepharose™ High Performance from 
GE Healthcare followed by the manufacturer manual. The chelating group 
coupled with agarose beads is precharged with Ni2+, which can selectively 
retain proteins with exposed histidine groups. 
Protein Expression in IVTT 
To in vitro translate VP30 protein, we use Invitrogen kit with following 
procedure: (1). Wash 25μl M-280 Tosylactivated beads/reaction 3X with 
1.0ml 1X PBS. (2). Treat work area and pipettes with RNase/DNase Away 
cleaner (3). Transfer 25μl of suspended beads to protein low-bind 
tubes/plate and remove PBS buffer (4). Add 50μl of Invitrogen IVTT 
master mix (Table 1). (5). Incubate 30ºC in plate in proteomaster/incubator 
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for 30min. (6). Add 50μl of feed reaction (Table 2). (7). Incubate 30ºC on 
plate in proteomaster/incubator for 3.5 hour. (8). Wash beads 3X with 
0.5ml 1X PBS. Freeze beads for later use here.  
 
Table 1. Invitrogen IVTT Master Mix components 
 
Table 2. Invitrogen IVTT Feeding Reaction components 
M-280 Tosylactivated beads are magnetic beads for small-scale 
purification. The VP30 coated beads are obtained after mixing M-280 
Tosylactivated magnetic beads with the IVTT reaction, and followed by 
magnetic separation to remove supernatant. 
SDS-PAGE 
SDS-PAGE gel. NuPAGE® Novex 4-12% Bis-Tris Gel 1.0 mm, 10 
well (InvitrogenTM # NP0321BOX), NuPAGE® Novex 4-12% Bis-Tris Gel 
1.0 mm, 12 well (InvitrogenTM # NP0322BOX) and NuPAGE® Novex 4-
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12% Bis-Tris Gel 1.0 mm, 15 well (InvitrogenTM # NP0323BOX);The 
running buffer were prepared by adding 50 ml 20X NuPAGE®MES to 950 
ml of deionizer water. The running conditions are: 200 constant voltages 
for 40 minutes. 
Silver stain. We expected the antibodies that eluted from beads will 
be in very low concentration, thus silver stain might be necessary in order 
to see the bands. The kit we used for silver stain is Pierce® Silver Stain Kit 
(Thermo #24612). All solutions were prepared as follow: Fixing Solution: 
30% ethanol: 10% acetic acid in ultrapure water; Sensitizer Working 
Solution: 40μl Sensitizer with 20ml ultrapure water; Stain Working Solution: 
400μl Enhancer with 20ml Stain; Developer Working Solution: 400μl 
Enhancer with 20ml Developer. The procedure summarized as follow: (1) 
Wash gel with ultrapure water twice for 5 minutes. (2) Fix the gel with 
Fixing Solution for 15 minutes, twice. (3) Wash the gel with 10% ethanol 
twice for 5 minutes. Then wash the gel with ultrapure water twice for 10 
minutes. (4) Sensitize the gel with Sensitizer Working Solution for 1 
minute, and then wash the gel with ultrapure water twice for 1 minute. (5) 
Stain the gel with Stain Working Solution for 30 minutes. (6) Wash the gel 
with ultrapure water twice for 20 seconds each. Then develop the gel with 
Developer Working Solution for 2~3 minutes until bands appear. (7) Stop 
with 5% acetic acid for 10 minutes.  
Depletion of virus specific antibodies from serum 
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To deplete target antibody, we first prepared the 1/250 dilution sera. 
For the ELISA experiments, we use 3% BSA in 1X PBS to make the 
dilution. To prepare depleted sera used to probe 10K random peptide 
microarray, we use incubation buffer to make the dilution. The incubation 
buffer was prepared as follow: 5ml of 30% BSA, 25ul of Tween 20, 5ml 
10x PBS, 40 ml ddH20. We then added VP30 beads from IVTT reaction 
that equivalent to certain amount of VP30 protein into the diluted sera in 
the low protein binding tubes (Eppendorf Protein LoBind Tubes). Then we 
shake the tube overnight in Rapid Translation System Proteomaster at 
37°C at 900 rpm, or in eppendorf Thermomixer R at 37°C at 1200 rpm. 
We spin down the beads, collect the antibody-depleted sera and keep the 
beads at 4°C the next day.  
To elute the bound antibodies from the VP30 on the beads, we used 
the procedure as follow: (1) prepare elution buffer by adding 11.1g 
Glycine-Hcl to 800ml dH2O, then adjusting pH from 3.8 to 5 and bring 
volume to 1liter with dH2O. (2) Elute bound antibodies with glycine buffer, 
pH=3.8 three times by mixing/vortexing for 5-10 minutes, then elute bound 
antibodies with glycine buffer, pH=5 three more times by mixing/vortexing 
for 5-10 minutes. (3) Collect the supernatant into a new tube and add 1/10 
the volume of 2M Tris buffer, pH=8.0 to neutralize the antibody in order to 
prevent denaturation of antibodies. 
Probing CIM 10K ver2 random peptide microarray with ASFV sera 
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Tecan automated processing. We first prepared the reagents as 
follow: (1) Blocking Buffer: 5 ml of 30% BSA, 6.9 ul of Mercaptohexanol, 
25 ul of Tween 20, 5 ml 10x PBS, 40 ml ddH20; (2) Incubation Buffer: 5 ml 
of 30% BSA, 25 ul of Tween 20, 5 ml 10x PBS, 40 ml ddH20. (3) Sera: 
Sera were prepared by 1/500 dilution of incubation buffer that prepared in 
(2). (4) Prewash buffer: 7.33% acetonitrile, 33% isopropanol and 0.55% 
triflouroacetic acid in nanopure water. (5) Secondary antibody: Goat Anti-
Swine IgG (H+L)-BlOT from BioFX (Cat No. 120-120-06) was diluted to 5 
nmol by using incubation buffer prepared in (2). (6) Tertiary antibody: 
Streptavidin Alexaflour 647 from Invitrogen was diluted to 5nmol by using 
incubation buffer prepared in (2). 
We prepared the slides by following procedures: (1) Place slides in a 
slide washer occupying only every other space to ensure good solvent 
flow. (2) Submerge slides in wash buffer and place on the rotating platform 
in the chemical fume hood that is set for slow speed (approximately 
setting 4) for 5 min. (3) Manually wash 1x in Tris Buffer Saline Tween20 
(TBST) buffer. (4) Manually wash 1x in ddH2O. (5) Spin and dry the slides 
at 1500 rpm for 5 min. 
We then use Tecan machine (HS 4800™ Pro) to automated process 
the slides. The procedures we used on Tecan were basically included: (1) 
Blocking the 10K microarray surface by incubating with blocking buffer for 
30 minutes. (2) Probe 10K random peptide microarray with pig sera. (3) 
Probe 10K random peptide microarray with anti-swine secondary antibody 
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for one hour. (4) Fluorescently labeling the secondary antibody by the 
streptavidin conjugated Alexaflour dye for one hour. 
Optimize the secondary antibody concentration. Since this is the 
first time in our lab to use anti-swain secondary antibody on Tecan. 
Optimize its concentration is necessary in order to get good 
immunosignatures of 10K microarray. Three different secondary antibody 
concentrations: 2 nmol, 5 nmol, 10 nmol, have been tested and their 
dynamic ranges were measured on Genepix. The concentration of the 
best dynamic range and the cleanest background was selected as the 
standard concentration for all the following experiments.  
Statistical analysis 
Principle component analysis (PCA). It is easy to plot a set of data 
with only two variables and visualize the correlation between them. 
However, in our experiment, the signals of thousands of peptides were 
measured across many different variables such as treatments or time 
points. With so much data organized in a multi-dimensional matrix, it 
becomes very challenging to make a visual inspection of the relationship 
between peptides and variables. One way to simplify the data is to reduce 
its dimensionality (Fig. 2). Several data decomposition techniques are 
available for this purpose, among them Principal Components Analysis 
(PCA). By performing a covariance analysis between factors, PCA can 
reduce the data to a few dimensions. PCA can also transform the data to 
a new set of variables (the principal components) and summarize the 
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features of the data. Since PCA contains most of the variants in the data, 
it can also be used in cluster analysis (Yeung and Ruzzo 2001).  
In this study, PCAs were performed by Genespring GX 7.3 from 
Agilent Technologies to find relevant components, or patterns, across 
samples or conditions. All PCAs were displayed in a two dimensions 
scatter plot view, with the two most important components on each axis. 
Each dot on the PCA plots represents a sera sample. The distance 
between two dots on the PCA plot can be interpreted as the differences of 
the immune responses.  
 
Figure 2.  Principle component analysis seeks a space of lower 
dimensionality. The projection of the data points (red dots) onto the lowest 
dimensionality (magenta line) maximizes the variance of the projected 
points (green dots). 
One way ANOVA test and Student t-test. In our study, one way 
analysis of variance (ANOVA) was used to determine if one given factor, 
such as with immunization or without immunization, had a significant effect 
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on the immune reactivties against peptides across any group that was 
studied. This model could be written as: 
 
The assumptions for this model are: (1) Corresponding to each factor 
level, there is a probability distribution of responses. (2) The probability 
distribution of all groups is normal. (3) Each probability distribution has the 
same variance. (4) Responses are statistically independent. The null 
hypothesis is that there is no difference in the mean peptide expression 
intensities across the groups we tested.  
A significant p-value from the 1-way ANOVA test would indicate that a 
peptide was expressed differently by at least one of the groups analyzed. 
In our study, the p-value cut-off was set to 1e-4. However, if there were 
more than 50 peptides that passed the restriction, only the top 50 peptides 
with the lowest p values were picked. We did not see much difference 
when using more than 50 peptides to cluster a heat map or to plot a PCA 
map. 50 peptides can hold enough representiveness but also minimize the 
noise. Some of the peptides may be falsely considered as statistically 
significant. To reduce overall error rate and the false discovery rate, we 
performed multiple testing corrections (MTC) after ANOVA or t test. The 
Benjamini and Hochberg MTC methods were used. Though they are not 
the most stringent MTC, they offer a good balance between discovering 
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statistically significant differences in peptide expression and protecting 
against false positives (Kim, Dougherty et al. 2002). 
GLAM2 motif and Bepipred linear epitope prediction. Gapped 
Local Alignment of Motifs (GLAM2) is a tool for discovering motifs in a 
group of DNA or protein sequences. We use GLAM2 to find the common 
motifs across a set of peptides we selected. The advantage of using 
GLAM2 is its ability to discover gapped motifs. GLAM2 will not only find 
the best motif in one run, but also performs it ten times to confirm its 
results.  
Further, we used the Bepipred linear epitope prediction tool 
(http://tools.immuneepitope.org/tools/bcell/iedb_input) to predict antibody 
epitopes by the protein sequence. BepiPred can predict the location of 
linear B cell epitopes by using a combination of hidden Markov models 
and a propensity scale method. The propensity scales for each of the 20 
amino acids includes hydrophilicity, flexibility, accessibility, turns, exposed 
surfaces, polarity and antigenic propensity of polypeptides chains.  
Once we got the predicted epitopes for the original protein, we 
compared them with the common motifs that were found among the 
selected peptides to see if they were alike. 
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Chapter 5 
RESULTS 
The antibody reactivity profiles of immunized and unimmunized pigs 
against random peptide microarray can be distinguished 
Because of the complexity of an immune-profile comprised of antibody 
responses to such a large number of peptides on our array, it was difficult 
to compare the profiles without data reduction. To reduce dimensions, 50 
out of the 9,786 peptides were selected as displaying the most significant 
differences in reactivity levels between immunization groups using a t test 
(p value ≤ 1.39e-11). We clustered 40 sera samples based on these 50 
peptides by Genespring 7.3. The hierarchical clustering algorithm 
Genespring 7.3 uses is the 'centroid' clustering method. In this method, 
the distance between two clusters is the distance between the averages of 
the data points under one branch and the averages of the data points 
under another. As shown on the heat map (Fig. 3(A)), only two pre-
immunization pigs were misclassified to the post-immunization group. The 
accuracy of grouping was 95%. From the PCA plot (Fig. 3(B)), although 
the two clusters were not separated very well by distance, we can still pick 
out the clusters of pre-immunization group and post immunization group. 
This reveals the ability of these 50 peptides to distinguish the different 
immunosignatures between ASFV antigen-immunized and unimmunized 
pigs.  
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Figure 3. Immunosignatures of British pigs from immunization groups. (A) 
Heat map generated by 50 peptides that were selected to distinguish 
between immunized pigs and umimmunized pigs. Blue on the heat map 
indicates the lowest expression level (the weakest binding between 
antibodies and peptides), and red indicates the highest expression level. 
The color bar at the bottom indicates the classification of pigs (Green 
represents immunized pigs and red represents unimmunized pigs). (B) 
Principle Component Analysis (PCA) plot showing all the immunized and 
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unimmunized pigs in (A). (C) PCA plot showing the clusters of immunized 
pigs from different groups.  
 
Earlier, we hypothesized that the pigs immunized with different 
antigens would have different immunosignatures. To test our hypothesis, 
19 peptides were selected by one way ANOVA test that most significantly 
distinguish 4 different post-immunization groups (p value≤1e-4). One way 
ANOVA test was used instead of t test because more than two groups of 
samples were involved in our comparison. We plotted a PCA to cluster 
those four groups. Interestingly, we found that group 4 pigs, which were 
immunized with two known immunodominant antigens, were separated 
from group1 and group 2, both of which were immunized with 20 unique 
antigens in addition to the two used for group 4 (to make a cleaner look of 
the PCA plot, group 3 was ignored due to its random distribution). To 
rationalize this separation between group 4 and groups 1&2, we suggest 
that the immunosignatures of the two immunodominant antigens were not 
the only antibody reactivites elicited by immunization with the pools of 
other antigens. 
29 
The antibody reactivity profiles of infected and uninfected French 
sera against random peptide microarray can be distinguished 
To determine if we can differentiate the immuno-profile of infected 
French pigs from the immuno-profile of the uninfected French pigs, seven 
peptides were selected using t test (p value≤1e-4). Using the heat map 
display, we can compare the reactivity profiles of these peptides, which 
also classified the two groups of pigs perfectly (Fig. 4(A)). The PCA plotted 
by these peptides also confirmed that four infected pigs were well 
separated from uninfected pigs (Fig. 4(B)). These seven peptides do not 
overlap with the 50 peptides we selected for distinguishing antigen-
immunized sera from unimmunized sera. We reasoned that a viral 
infection may elicit different immuno-responses from the immunizations 
with a limited number of antigens and such differences influenced the 
reactivity profiles against peptides on the array. There could be some 
other important antigens that play important roles during the viral infection. 
The strong expression level of these seven peptides may reveal the 
reactivities of those undiscovered antigen responses. 
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Figure 4. Immunosignatures of vial infected French pigs. (A) Heat map 
generated by seven peptides that were selected to distinguish between 
infected French pigs and uninfected French pigs. The color bar at the 
bottom indicates the classification of pigs (brown represents vial infected 
French pigs and purple represents uninfected French pigs). (B) PCA plot 
showing the same pigs in (A).  
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The antibody reactivity profiles of infected and uninfected British 
pigs against random peptide microarray can be distinguished 
The sera from British infected pigs were received after the first round 
of experiments which tested the sera from antigen immunized pigs and 
sera from vial infected French pigs. These British infected pigs were not 
raised in a controlled, pathogen-free environment. Therefore, unlike 
specific pathogen free (SPF) pigs from France, British pigs likely to have 
been exposed to other pathogens, so would be expected to have more 
complex immunological reactivities and thus more similar to the wild pigs 
and the pigs in food industry. Therefore, it is meaningful to test the French 
sera samples separately from the British sera samples. Since we don’t 
have pre-infection sera samples, the unimmunized British sera were 
assayed as the controls. 50 peptides were selected as displaying the most 
significant differences in reactivity levels between these two groups using 
a t test (p value≤6.67e-20). As shown on the heat map that generated by 
these 50 peptides, we can clearly see that the reactivity profiles of these 
peptides were distinct between the infected pigs and the control pigs (Fig. 
5 (A)). Also, the classifications of the two groups were perfect. From the 
PCA plot, a significant separation between these two groups can be 
observed. Although it is insufficient to have tested only two samples before 
making a conclusion, the immnosignatures captured with the 10K random 
microarray are consistent and reproducible for pigs with different immune 
histories. 
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Figure 5. Immunosignatures of vial infected British pigs. (A) Heat map 
generated by 50 peptides that were selected to distinguish between 
infected British pigs and unexposed pigs. The color bar in the bottom 
indicates the classification of pigs (Green represents vial infected British 
pigs and red represents uninfected pigs). (B) PCA plot showing the same 
pigs in (A). 
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The antibody reactivity profiles of all infected and all uninfected sera 
against random peptide microarray can be distinguished fairly well 
We combined the expression profiles from infected British sera and 
infected French sera and endeavored to determine whether we can 
segregate them from unexposed sera. We picked the 50 peptides that 
most significantly distinguished these two groups by a t test and clustered 
these peptides to make a heat map (p value ≤ 2.1e-15). Using the heat 
map display, we can see two distinctive profiles. Although a few of the 
unexposed pigs were misclassified, most of the pigs were correctly 
clustered to its own group. In general, the profiles from unexposed pigs 
had lower expression levels compared to the profiles of infected pigs. This 
may indicates that the antibodies from the infected pig sera display higher 
reactivities to these peptides. The PCA plot also confirmed the separation 
between infected and uninfected pigs (Fig. 6(B)). We also compared these 
50 peptides with the 50 peptides selected to distinguish British infected 
sera and unexposed sera. We found only one common peptide. The 
possible explanation could be: although British infected pigs and French 
infected pigs show similarities in their binding patterns, their highest 
binding reactivities are distinct.  
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Figure 6. Immunosignatures of vial infected pigs. (A) Heat map generated 
by 50 peptides that were selected to distinguish between all infected pigs 
and all unexposed pigs. The color bar at the bottom indicates the 
classification of these pigs (Green represents vial infected pigs and red 
represents uninfected pigs). (B) PCA plot showing the same pigs in (A). 
35 
The antibody reactivity profiles of ASFV or ASFV antigen exposed 
and unexposed sera against random peptide microarray can be 
distinguished 
In this experiment, immunosignatures were gathered from all the pigs. 
Although these pigs had different origins and were exposed to different 
immunogens, the most obvious difference that can separate them is that 
some pigs were exposed to ASFV – either ASFV antigens or the 
attenuated virus – while the others were not. We selected 50 peptides that 
have the best p values in the t test and clustered them into a heat map (p 
value ≤ 3.86e-10). Using the heat map display, we can identify two major 
patterns of antibody reactivity profiles. Although the classification of pigs 
was not perfect, 85% of the immunosignatures were correctly grouped to 
its own class. We also noticed that the pattern of reactivity profiles here 
are very similar to the immunized British pigs. The PCA in Fig. 7(B) and 
Fig. 7(C) were plotted by the same 50 peptides we selected. Although the 
separations were not very clear, all the pigs tended to aggregate to their 
own group, especially the unexposed pigs. The highly concentrated 
distribution of unexposed pigs on the PCA reveals the fewer varieties in 
immunosignatures, which is immunogically reasonable.  On the same 
PCA, we colored the pigs by their immunization strategies in order to see 
if we could identify the subgroups of exposed pigs. Although the 50 
peptides were not meant to identify these subgroups, we still found the 
British infected pigs have obvious separation from other exposed pigs. 
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French infected pigs also separate from other subgroups to a certain 
extent. However, the four groups of British antigen-immunized pigs could 
not be separated. This may indicate that the immunosignatures of viral 
infected pigs are more diverse than the immunosignatures of antigen 
immunized pigs. Also, undivided subgroups of immunized pigs may 
suggest that there are some common reactivites that are dominant over 
the distinct reactivities. Such reactivites might be recognizing VP30 and 
VP72, or the recombinant vaccinia virus vectors that were used to boost 
the immunizations. 
 
 
Figure 7. Immunosignatures of ASFV/ASFV antigen-exposed pigs. (A) 
Heat map generated by 50 peptides that were selected to distinguish 
between ASFV/ASFV antigen-exposed pigs and unexposed pigs. The 
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color bar at the bottom indicates the classification of the pigs (Green 
represents the ASFV/ASFV antigen-exposed pigs and red represents the 
unexposed pigs). (B) PCA plot showing the same pigs in (A). The red dots 
represent unexposed pigs and the green dots represent the ASFV/ASFV 
antigen-exposed pigs. (C) PCA plot showing the same pigs in (A). Red 
dots represent ASFV/ASFV antigen-exposed pigs, green dots the vial 
infected French pigs, purple dots the vial infected British pigs, blue dots 
the group 4 pigs, and the cyan dots all the pigs from group1, group2 and 
group 3.  
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The antibody reactivity profiles of VP30/VP72-immunized pigs and 
ASFV or ASFV antigen-unexposed pigs are poorly distinguished 
British pigs from group 4 have been exposed to VP30 and VP72. To 
test the sensitivity of our 10K random peptide microarray, we compared 
group 4 immunosignatures with all unexposed immunosignatures. Unlike 
most of the other experiments that hundreds of peptides can pass the t 
test, only 14 peptides passed the t test (p value ≤ 1e-4), which reveals that 
there are a smaller number of differences between immunosignatures 
from group 4 pigs and immunosignatures from unexposed pigs. Using the 
heat map display, we could not see clear patterns of the expression 
profiles, although the classifications of the pigs were fairly accurate (90%). 
On the PCA plot, the unexposed pigs were scattered and there was no 
clear separation between immunized group and unexposed group. This 
result may confirm the assumption we suggested earlier: VP30 and VP72 
may not be the antigens that elicit the dominating antibody responses in 
the context of antigen as opposed to infection. Other unrevealed ASFV 
antigens, or the vaccinia virus that used to boost the immune-response, 
may elicit stronger B cell response than VP30 and VP72.  
39 
 
Figure 8. Immunosignatures of VP30/VP72 immunized pigs. (A) Heat map 
generated by 14 peptides that were selected to distinguish between 
VP30/VP72 immunized pigs and all unexposed pigs. The colored bar at 
the bottom indicates the classification of the pigs (Green represents 
VP30/VP72 immunized pigs and red represents unexposed pigs). (B) PCA 
plot showing the same pigs in (A). 
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The antibody reactivity profiles of vaccinia-infected and ASFV-
infected British sera against random peptide microarrays are well 
separated 
Group 4 pigs were immunized with only two antigens, and followed by 
vaccinia boost. From the analysis of the earlier experiments, we have 
reason to believe that VP30 and VP72 may not be the cause of the 
dominant immunoresponses in group 4, which leaves vaccinia as an 
obvious suspect. If such hypothesis is true, we may assume group 4 as a 
vaccinia-infected group. Under such circumstance, we could compare the 
immunosignatures of group 4 to the immunosignatures of ASFV infected 
British pigs in order to see if our 10K random peptide microarray could 
differentiate two similar, but different, viral infections. To make this 
experiment more relevant, we removed the peptides that may represent 
the anti-VP30 antibody response from the selection pool (all 9, 786 
peptides). We selected 44 peptides that could distinguish between these 
two groups from the remaining peptides using the t test (p value ≤ 1e-4). 
From the heat map generated by these 44 peptides, we can clearly see 
two distinct patterns of reactivity profiles.  Also, the classifications of the 
tested pigs were perfect. The PCA map also shows clear separation 
between the two groups without any misclustering. The vaccinia and 
ASFV are both large double strained DNA viruses, and share a similar 
virus structure and replication strategies. If our 10K random peptide 
microarray can differentiate between the immunosignatures of these two 
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similar viruses, it is also feasible that our microarray could differentiate 
ASFV from other viral infections. Thus, the 10K random peptide 
microarray has the potential to be a diagnostic for ASF. 
 
 
Figure 9. Immunosignatures of vaccinia-infected pigs and ASFV infected 
British pigs. (A) Heat map generated by 44 peptides that were selected to 
distinguish between vaccinia-infected pigs and ASFV infected British pigs. 
The color bar at the bottom indicates the classification of pigs (Green 
represents ASFV infected British pigs and red represents vaccinia-infected 
pigs). (B) PCA plot showing the same pigs in (A). 
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Protein expression and purifications 
VP30 expression in IVTT reaction. The VP30 LEE was successfully 
constructed by assembling three cassettes: Trx_Prom (promoter cassette, 
422 bp), VP30 ORF (615 bp), and T7_His_Term (terminator cassette, 222 
bp). The full length LEE is 1259 bp. We confirmed the full length LEE on 
an agarose gel (Fig. 10).  
 
Figure 10. The full length construct of VP30 LEE on 1.0% agarose gel 
Once the VP30 LEE was constructed, we started to translate VP30 
LEE in an IVTT reaction. We set up twenty 100μl IVTT reactions in order 
to get enough protein for the ELISA and depletion experiments. After 
mixing M-280 Tosylactivated magnetic beads with the IVTT reaction, 
followed by magnetic separation to remove supernatant, VP30 coated 
magnetic beads are obtained. 
All of the VP30 coated magnetic beads were combined into one tube 
and resuspended in PBS buffer. VP30 concentration was measured by 
running a SDS-PAGE gel. We prepared a series of protein standards by 
loading different amounts of BSA (1μg, 2μg, 5μg and 10μg) on the same 
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gel. By comparing with the BSA standards, the concentration of the final 
product was roughly 0.5~0.8 μg/μl (Fig. 11). We then stored the VP30 
protein at 4ºC. 
 
Figure 11. SDS-PAGE gel of VP30 protein. (A) VP30 protein by IVTT 
expression: Lane 1: 0.5μl of the 50μl final product. Lane 2: 1μl of the 50μl 
final product. Lane 3: 2μl of the 50μl final product. 4: 5μl of the 50μl final 
product. 5: 10μl of the 50μl final product. (B) Assessed yield of VP30 
protein by loading different amount of BSA. Lane 1: 1μg BSA. Lane 2: 2μg 
BSA. Lane 3: 5μg BSA. Lane 4: 10μg BSA. 
Protein expressions in E.coli. We decided to use thioredoxin (trx) as 
the control protein since it could be made recombinantly and thus be cost 
efficiently. We used the empty pET 32 b+ vector as the template.  The 
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thioredoxin protein itself is about 13 kDa, but with the additional tags that 
are part of the pET 32b+ plasmid such as the S and His tags, the total 
weight of the entire control protein is ~20kDa. Following the procedure we 
described earlier, we successfully induced the control protein in the BL21 
E.coli by IPTG (Fig. 12). 
 
Figure 12. The control protein was expressed in E.coli.  (A) Soluble E.coli 
secretion. Lane 1: Soluble proteins before inducement. Lane 2: Soluble 
proteins after inducement. (B) Insoluble E.coli secretion. Lane 1: Insoluble 
proteins before inducement. Lane 2: Insoluble proteins after inducement. 
Purification of the control protein. To purify the control protein from 
E.coli extract, we performed histidine-tagged protein purification. The Ni 
Sepharose™ High Performance beads from GE healthcare were used to 
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selectively retain the histidine-tagged thioredoxin. Following the procedure 
provided by the manufacturer, we successfully purified the control protein. 
By comparing with BSA standards, we also evaluated the concentration of 
the purified protein. The concentration of the protein from the first, second, 
and third washes were 1.2mg/μl, 0.6 mg/μl, 0.24 mg/μl, respectively.  
 
 
Figure 13. SDS-PAGE gel of the purified Thioredoxin protein (A) The flow 
through from the purification and the purified Thioredoxin protein. Lane1: 
Flow through from binding buffer. Lane 2: Flow through from the first wash. 
Lane 3: Flow through from the second wash. Lane 4: Flow through from 
the third wash. Lane 5: Flow through from the fourth wash. Lane 6: Flow 
through from the fifth wash. Lane 7: Thioredoxin from the first elution. 
Lane 8: Thioredoxin from the second elution. Lane 9: Thioredoxin from the 
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third elution. (B) Assessed thioredoxin yield by loading different amounts 
of BSA. Lane 1: 1μg BSA. Lane 2: 2μg BSA. Lane 3: 5μg BSA. Lane 4: 
10μg BSA. 
ELISA test for using VP30 protein as the coating reagent 
To validate the VP30 protein we made by IVTT, TMB ELISA was 
performed. Both the VP30 and control proteins were coded onto the 96 
well plates. Both pre-immunization serum and post-immunization serum of 
two individual pigs (395 and 403) were selected as the test sera. The 
ELISA result is shown in the Fig. 14. The anti-VP30 antibody titer from 
both pigs increased about four-fold after immunization. This is consistent 
with the former ELISA test. The titer of the control groups, however, did 
not show many differences between pre-immunization sera and post-
immunization sera, which indicates the antibody titer we detected in the 
test group was specific.  
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Figure 14. ELISA result for VP30 validation. Blue & Green bar: Pre-
immunization serum. Red & purple bars: Post-immunization serum. Both 
green and red bars represent the titer from VP30 coded wells. Both green 
and purple bars represent the titer from thioredoxin coded wells (controls). 
 
ELISA test for anti-VP30 depleted serum 
Once the identity of VP30 protein made by IVTT reaction was confirmed, 
we began performing anti-VP30 antibody depletion tests. First, we wanted 
to test whether the VP30 protein we made by IVTT could pull down the 
anti-VP30 antibodies. Sera from pig 395 were chosen in the experiment 
for its high anti-VP30 antibody titer. Three different amounts of VP30 
proteins were added to 1/250 diluted post-immunization serum of pig 395. 
After overnight incubation with constant shaking at 37 ºC, we performed 
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an ELISA test for these antibody-drained sera. From the ELISA data (Fig. 
15), the depletion process drastically decreased the titer of anti-VP30 
antibodies to a level even lower than that of the pre-immunization serum. 
Thus, we believe the depletion was thorough and complete. However, 
adding more than 5 μg of protein did not make an obvious difference in the 
matter of titer changes. Three samples of British infected sera were also 
tested in this ELISA. All three sera showed high anti-VP30 antibody 
activity. 
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Figure 15. ELISA results from the first depletion test. “395 pre” is 
nondepleted pre-immunization serum of the pig 395. “395 post” is the 
nondepleted post-immunization serum of the pig 395. “5μg”, “10μg” and 
“20μg” represent the sera depleted by the corresponding amount of VP30 
protein. “TQ13” and “MI92” are the samples of British infected pig sera. 
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ELISA test to determine the VP30 quantity required for anti-VP30 
antibody depletion 
Although we already confirmed that the VP30 protein we made can 
successfully deplete anti-VP30 antibodies, the optimal VP30 dosage we 
should use remains uncertain. The overdose of VP30 may cause 
unspecific binding and pull down antibodies that are unrelated to VP30 
during the depletion. To avoid such a situation, we tried to determine the 
minimum dosage of VP30. We depleted post-immunization pig 395 sera 
with five different amounts of VP30 protein:  0.1μg, 0.2μg, 0.5μg, 1 μg and 
2 μg. We then tested the anti-VP30 antibody titer of these sera, and 
plotted the data as seen in Fig.16. The very first thing we noticed from the 
data was the significantly larger standard deviations among replicates. We 
believe these deviations are the result of unevenly coated wells. In the 
coating process, we noticed the beads holding VP30 were clogged and 
could not be suspended evenly. After remaking the VP30 proteins and 
using the freshly prepared VP30 in subsequent depletion tests, we found 
the standard deviations were back to normal. From this test, we also found 
that the anti-VP30 antibody titer tends to increase as we decrease the 
dosage of VP30. The changes, however, were not very significant.  
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Figure 16. ELISA results from the second depletion test. The “pre” is 
nondepleted pre-immunization serum of the pig 395. The “post” is the 
nondepleted post-immunization serum of the pig 395. “0.1 μg”, “0.2 μg” 
and “0.5 μg” “1 μg” and “2 μg” represent the sera that was depleted by the 
corresponding amount of VP30 protein.  
Probing 10K random peptide microarray with anti-VP30 antibody 
depleted serum 
Once we had validated the VP30 protein and tested our depletion 
strategy, we began preparing depleted sera for probing experiments 
against a peptide microarray. We depleted post-immunization sera with 
the control protein and two different amounts of VP30 protein separately. 
Also, the pre-immunization sera were depleted by the control protein and 
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VP30 protein separately. By comparing the peptide expression profiles of 
depleted and nondepleted post-immunization sera, we hoped to sort out a 
set of peptides that represent anti-VP30 antibody activity. The logic behind 
this was that once the anti-VP30 antibody was depleted, the peptides that 
had bound to the antibody should no longer light up on the microarray. 
However, we were not able to find such peptides by t test. In fact, none of 
the peptides had significant changes in expression level after depletion (p 
value≤1e-4). We rationalized that the anti-VP30 antibody may not be 
completely depleted for two reasons. Firstly, VP30 was phosphorylated 
during the post translational modification (Prados, Vinuela et al. 1993; 
Hernaez, Escribano et al. 2008). Antibody elicited by phosphorylated 
VP30 may not be recognized by native VP30. Secondly, during infection, 
VP30 interact with other proteins such as ribonucleoprotein K (RNP-K) 
(Hernaez, Escribano et al. 2008). Thus, antibody induced by these 
conjugated VP30 may also be unrecognized by native VP30 we made by 
IVTT.   
Elution of anti-VP30 antibodies from IVTT beads 
Since the depletion experiment could not identify the peptides that had 
bound to the anti-VP30 antibodies, we changed our strategy. We began by 
recovering the antibodies bound to the VP30 protein by eluting with an 
acidic glycine hydrochloride (glycine-HCl) buffer. We eluted the VP30 
protein beads three times with a buffer of pH3.8 and then another three 
times with a buffer of pH5.0. As can be seen in the silver stained SDS-
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PAGE gel in Fig. 17, the majority of the antibodies were released in the 
first elution. The two fat bands are likely to be the full length antibody (the 
upper band) and the heavy chain of the antibody (the lower band). After 
the sixth elution, the remaining beads were boiled so every possible 
protein left on the beads could be collected. Although it is very dim, the 
band of the VP30 protein is still visible (see the arrow).  
 
Figure 17. Silver-stained SDS-PAGE gel of purified Anti-VP30 antibody. 
Lane 1: Flow through from the first elution with pH=5.0 elution buffer. Lane 
2: Flow through from the second elution with pH=5.0 elution buffer. 3. Flow 
through from the third elution with pH=5.0 elution buffer. 4. Flow through 
from the fourth elution with pH=3.8 elution buffer. 5. Flow through from the 
fifth elution with pH=3.8 elution buffer. 6. Flow through from the sixth 
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elution with pH=3.8 elution buffer. 7. Leftover proteins on the beads 
collected from boiling in 4x loading dye with 20% BME 
Probing 10K random peptide microarray with eluted anti-VP30 
antibody 
After we recovered the anti-VP30 antibodies, we probed for these 
antibodies on a microarray. We then compared the peptide reactivates 
with those of unimmunized sera. The five peptides that passed the t test 
are:  
(1) WYQLDAHESYINNLVFP  
(2) TMETAKQKTYNILIWYY  
(3) AQYMLKLIHYHLIAFQG  
(4) SHYNHTIYLRIKKPNAY  
(5) WWVITAGWWGIAKIEAG 
Using the heat map display, we can see that these peptides show the 
highest expression level in the retrieved antibody group, the lowest 
expression in the pre-immunization group, and medium expression in the 
post-immunization group. Such trends also meet our expectations. 
 
Figure 18. Heat map clustered by 5 selected peptides 
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The binding of monospecific antibodies to antigens can be described 
by the “lock and key” model: these antibodies bind only to antigens with a 
specific epitope. Thus it was predicted that there would be a common 
motif among the peptides that bound to the anti-VP30 antibody. When the 
sequence of the first 4 peptides we selected earlier was analyzed by the 
motif-finding program GLAM2, the motif SHYNNLIF was found (peptide 5 
was excluded since it is very different from the other four and contains 
many tryptophans. This amino acid is considered a sticky residue that may 
enhance nonspecific binding of antibody). Though not very strong a motif, 
it was found repeatedly over ten runs. Random peptides analyzed the 
same way were found to have similarly long motifs without such good 
consistency or scores. 
Later, we included the original protein sequence of VP30 and aligned it 
with the 4 peptides. The best motif we found was the same as the one we 
found earlier. The motif was also found repeatedly over multiple runs.  
We then tried to find the antibody epitopes for VP30 to see if it 
matched the motif we found. Of the 4 major epitopes predicted by the 
IEDB antibody epitope prediction program (Fig. 19), none matched the 
motif we found. However, the lack of matches does not necessary mean 
our finding is wrong since the IEDB epitope prediction is based on its own 
algorithm that is not always very accurate. Also, IEDB searches only for 
linear epitopes and is unable to find conformational epitopes.  
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Figure 19. Analysis of motif alignment and VP30 epitope prediction. (A) 
Best motif found among 4 high-binding peptides. (B) Best motif found 
among four high-binding peptides and VP30 protein. (C) Predicted linear 
epitopes by Bepipread prediction. (D) Bepipred linear epitope prediction 
score.  
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Chapter 6 
DISCUSSION 
We have investigated the antibody responses of different ASFV 
infections and antigen immunizations with a new microarray platform that 
features 9,786 random-sequence peptides. By probing this microarray 
with infected and immunized sera, first, we confirmed the hypothesis that 
antibody responses against ASFV antigen library immunizations and 
infections could be detected on the random peptide array.  
Second, we identified a set of 50 peptides that could distinguish 
antigen immunized from unimmunized sera with 95% accuracy. Of the four 
groups of antigen immunized sera, group 4 was most different from the 
other three groups, which may indicate that the additional 20 randomly 
selected antigens can influence the immune responses elicited from VP30 
and VP72.  
Third, we discovered that ASFV infected French and British sera can 
be distinguished from uninfected sera with 100% accuracy. Although the 
sample size was small, the clear separation of infected and uninfected 
sera on the PCA plot demonstrates the microarray's potential for 
diagnostics.  
Fourth, we tested if unexposed sera could be distinguished from 
“exposed” sera - that is, either infected or library antigen immunized sera. 
We found that while the separation between the groups was insignificant 
on PCA, the accuracy was still acceptable (about 85%). The exposed sera 
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were much more scattered on the plot than the unexposed sera, which 
may indicate a wide diversity of immune responses among the immune 
stimulated pigs. We also observed that unlike infected sera, the different 
groups of the immunized sera do not seem to be segregated by the same 
PCA analysis. Considering that all the immunizations were boosted with a 
ASFV antigen-carrying, recombinant vaccinia virus vector, we reasoned 
that the vaccinia may strongly influence antibody reactivities against 
random peptides. Many literatures have demonstrated that a minority of 
vaccinees boosted with vaccinia virus are mainly responded to the 
vaccinia virus (Gallimore, Cranage et al. 1995; Goulder, Phillips et al. 1997; 
Hanke, Samuel et al. 1999), which indicate that the antibody reactivities 
we detected on peptide array may mainly reflect the immno-responses 
against vaccinia. On the other hand, there are many similarities between 
vaccinia and ASFV (Afonso, Alcaraz et al. 1992). The ability of our peptide 
microarray to distinguish ASFV infections from a very similar viral infection 
also underscores its potential as an ASF diagnostic.   
Finally, by probing the random peptide microarray with the purified 
anti-VP30 antibody, we found a unique set of peptides that bind to anti-
VP30 antibody. Using motif finding and alignment approaches, we found a 
common motif among the peptides and the original VP30 protein 
sequence. This may indicate that even though the random peptides on our 
microarray have no homology to the VP30 protein, the binding signals we 
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detected are not nonspecific responses. Also, it holds the potential of 
using the random peptide microarray to predict the immunogenic antigens.  
In sum, this study not only showed the feasibility of CIM's 10K random 
peptide microarray as a powerful platform for assessing antibody 
responses to viral infections and viral antigen immunizations, and also 
confirmed that pig serum antibody repertories possess sufficiently rich 
source of immune information for highly useful diagnostic discovery. To our 
knowledge, this is the first study that applies this platform to assess a pig 
disease. The peptides we selected to distinguish ASFV antigen-
immunized pigs from unimmunized pigs should be carefully used since the 
selection were probably influenced by the vaccinia-boost. The peptides 
selected to distinguish infected pigs from uninfected pigs may be 
considered as the candidates of ASF diagnostic peptides. Given the small 
sample size, our experiment can only be regarded as a preliminary study. 
More ASFV-infected samples are required for the validation and the further 
selections. Nevertheless, the obviously distinct pattern of antibody profiles 
from exposed pigs confirmed a strong correlation between the antibody 
responses to ASFV infection, which could lead us to a successful path of 
diagnosis.   
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